Surrozen (NASDAQ:SRZN) Major Shareholder Buys $300,339.00 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 15,100 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was purchased at an average cost of $19.89 per share, for a total transaction of $300,339.00. Following the acquisition, the insider owned 989,893 shares of the company’s stock, valued at approximately $19,688,971.77. This trade represents a 1.55% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, December 5th, Group Gp Lp Column III acquired 30,884 shares of Surrozen stock. The shares were acquired at an average cost of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III bought 5,266 shares of Surrozen stock. The stock was acquired at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III purchased 315,457 shares of Surrozen stock. The stock was acquired at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Trading Down 3.0%

Shares of SRZN opened at $18.49 on Friday. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $24.94. The company has a market cap of $158.46 million, a PE ratio of -0.83 and a beta of 0.58. The stock has a 50-day moving average price of $17.97 and a 200-day moving average price of $13.57.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The company had revenue of $0.98 million during the quarter. As a group, analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SRZN shares. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SRZN. Citadel Advisors LLC increased its holdings in shares of Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after buying an additional 3,424 shares during the period. Geode Capital Management LLC boosted its holdings in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the period. Acuta Capital Partners LLC grew its position in Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after acquiring an additional 8,415 shares during the last quarter. Stonepine Capital Management LLC increased its stake in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares during the period. Finally, Vanguard Group Inc. lifted its position in Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after purchasing an additional 47,468 shares during the last quarter. 66.57% of the stock is owned by institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.